WaferGen Bio-systems (NASDAQ: WGBS) and Vascular Solutions (NASDAQ:VASC) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitabiliy, valuation, dividends, institutional ownership and earnings.

Risk and Volatility

WaferGen Bio-systems has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, Vascular Solutions has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.

Institutional and Insider Ownership

49.8% of WaferGen Bio-systems shares are held by institutional investors. Comparatively, 80.2% of Vascular Solutions shares are held by institutional investors. 5.8% of WaferGen Bio-systems shares are held by company insiders. Comparatively, 6.9% of Vascular Solutions shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares WaferGen Bio-systems and Vascular Solutions’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
WaferGen Bio-systems N/A N/A N/A ($6.30) -1.10
Vascular Solutions N/A N/A N/A $0.70 80.00

WaferGen Bio-systems is trading at a lower price-to-earnings ratio than Vascular Solutions, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for WaferGen Bio-systems and Vascular Solutions, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
WaferGen Bio-systems 0 0 0 0 N/A
Vascular Solutions 0 4 0 0 2.00

Vascular Solutions has a consensus target price of $55.50, indicating a potential downside of 0.89%. Given Vascular Solutions’ higher possible upside, analysts clearly believe Vascular Solutions is more favorable than WaferGen Bio-systems.

Profitability

This table compares WaferGen Bio-systems and Vascular Solutions’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
WaferGen Bio-systems -153.30% -463.27% -111.39%
Vascular Solutions 13.02% 15.78% 14.30%

Summary

Vascular Solutions beats WaferGen Bio-systems on 7 of the 8 factors compared between the two stocks.

WaferGen Bio-systems Company Profile

WaferGen Bio-systems, Inc. (WaferGen) is engaged in the development, manufacture and sale of genomic technology solutions for single-cell analysis (SCA) and clinical research. The Company focuses on marketing an open format genetic analysis system, the WaferGen SmartChip System. The Company’s ICELL8 Single-Cell System is a platform that can isolate a range of single cells and process specific cells for analysis, including Next Generation Sequencing (NGS). ICELL8 is based upon the Company’s SmartChip platform, which is also used for profiling and validating molecular biomarkers. The Company’s SmartChip is a micro-fabricated chip comprising a range of massively-parallel micro wells that are physically separated from each other. It offers SmartChip System Capabilities, SmartChip Single-Cell Isolation System, SmartChip Target Enrichment (TE) System and Apollo 324 Library Preparation.

Vascular Solutions Company Profile

Vascular Solutions, Inc. is a medical device company focused on bringing clinically advanced solutions to the market for treating coronary and peripheral vascular disease. The Company’s product line consists of devices and services that are sold to interventional cardiologists, interventional radiologists, electrophysiologists and vein practices around the world. Its products include GuideLiner catheters, Pronto catheters, Vein catheter reprocessing, Micro-introducer kits, Hemostatic patches, Radial access products, Langston catheters and D-Stat Flowable hemostat. The Company’s product portfolio includes a spectrum of over 90 products consisting of approximately 900 stock keeping units (SKUs) covering an array of blood clotting devices, extraction catheters, access catheters, guide extension catheters, micro-introducer kits, guidewires, snare and retrieval devices, a reprocessing service for radiofrequency catheters and a laser and procedure kits for the treatment of varicose veins.

Receive News & Ratings for WaferGen Bio-systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WaferGen Bio-systems Inc. and related companies with MarketBeat.com's FREE daily email newsletter.